BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

OTLK upcoming catalysts

Outlook Therapeutics, Inc.: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 0 readout(s) and 3 FDA event(s). Subscribe to OTLK (.ics).

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No trials in this window.

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-07-29PDUFA date (company-disclosed)date passedOutlook Therapeutics, Inc. OTLKbevacizumab-vikgPDUFA July 29, 2026 - Outlook Therapeutics, Inc. (bevacizumab-vikg)
2026-07-24FDA approvalapprovedOUTLOOK THERAPEUTICS, INC. OTLKLYTENAVAApproved 2026-07-24: LYTENAVA (BLA761320 ORIG1)
2025-12-30Complete response lettercomplete responseOutlook Therapeutics, Inc. OTLKbevacizumab-vikgCRL 2025-12-30: Outlook Therapeutics, Inc. BLA 761320 (bevacizumab-vikg injection)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No readouts in the last 12 months.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.